Back to Search Start Over

International Prospective Registry of Acute Coronary Syndromes in Patients With COVID-19.

Authors :
Kite, Thomas A.
Ludman, Peter F.
Gale, Chris P.
Wu, Jianhua
Caixeta, Adriano
Mansourati, Jacques
Sabate, Manel
Jimenez-Quevedo, Pilar
Candilio, Luciano
Sadeghipour, Parham
Iniesta, Angel M.
Hoole, Stephen P.
Palmer, Nick
Ariza-Solé, Albert
Namitokov, Alim
Escutia-Cuevas, Hector H.
Vincent, Flavien
Tica, Otilia
Ngunga, Mzee
Meray, Imad
Source :
Journal of the American College of Cardiology (JACC). May2021, Vol. 77 Issue 20, p2466-2476. 11p.
Publication Year :
2021

Abstract

<bold>Background: </bold>Published data suggest worse outcomes in acute coronary syndrome (ACS) patients and concurrent coronavirus disease 2019 (COVID-19) infection. Mechanisms remain unclear.<bold>Objectives: </bold>The purpose of this study was to report the demographics, angiographic findings, and in-hospital outcomes of COVID-19 ACS patients and compare these with pre-COVID-19 cohorts.<bold>Methods: </bold>From March 1, 2020 to July 31, 2020, data from 55 international centers were entered into a prospective, COVID-ACS Registry. Patients were COVID-19 positive (or had a high index of clinical suspicion) and underwent invasive coronary angiography for suspected ACS. Outcomes were in-hospital major cardiovascular events (all-cause mortality, re-myocardial infarction, heart failure, stroke, unplanned revascularization, or stent thrombosis). Results were compared with national pre-COVID-19 databases (MINAP [Myocardial Ischaemia National Audit Project] 2019 and BCIS [British Cardiovascular Intervention Society] 2018 to 2019).<bold>Results: </bold>In 144 ST-segment elevation myocardial infarction (STEMI) and 121 non-ST-segment elevation acute coronary syndrome (NSTE-ACS) patients, symptom-to-admission times were significantly prolonged (COVID-STEMI vs. BCIS: median 339.0 min vs. 173.0 min; p < 0.001; COVID NSTE-ACS vs. MINAP: 417.0 min vs. 295.0 min; p = 0.012). Mortality in COVID-ACS patients was significantly higher than BCIS/MINAP control subjects in both subgroups (COVID-STEMI: 22.9% vs. 5.7%; p < 0.001; COVID NSTE-ACS: 6.6% vs. 1.2%; p < 0.001), which remained following multivariate propensity analysis adjusting for comorbidities (STEMI subgroup odds ratio: 3.33 [95% confidence interval: 2.04 to 5.42]). Cardiogenic shock occurred in 20.1% of COVID-STEMI patients versus 8.7% of BCIS patients (p < 0.001).<bold>Conclusions: </bold>In this multicenter international registry, COVID-19-positive ACS patients presented later and had increased in-hospital mortality compared with a pre-COVID-19 ACS population. Excessive rates of and mortality from cardiogenic shock were major contributors to the worse outcomes in COVID-19 positive STEMI patients. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
07351097
Volume :
77
Issue :
20
Database :
Academic Search Index
Journal :
Journal of the American College of Cardiology (JACC)
Publication Type :
Academic Journal
Accession number :
150231196
Full Text :
https://doi.org/10.1016/j.jacc.2021.03.309